Email a Friend
To: (email address)
From: (email address)
Email Subject:
Note: (optional)
255 character limit
Hyperlipidemic patients with comorbid conditions are at increased risk and some patients may need aggressive treatment to reach LDL-C goals.1-3
In this section you can review results from clinical trials on LDL cholesterol in which CRESTOR® (rosuvastatin calcium) was used as an adjunct to diet in patients with type 2 diabetes and dyslipidemia.
Click on the "+" and "—" signs to expand and collapse the clinical information.
‡Subject to eligibility. Restrictions apply. Click here for eligibility information.
LDL-C goal attainment (<100 mg/dL) in patients with type 2 diabetes and dyslipidemia4,5
Adapted from the ANDROMEDA and URANUS Trials
LDL-C reductions vs atorvastatin in patients with type 2 diabetes and dyslipidemia4
Adapted from the ANDROMEDA Trial
URANUS study for LDL-C Reductions
You may report side effects related to AstraZeneca products by clicking here.